Rep. April McClain Delaney Unloads STERIS plc (NYSE:STE) Shares

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $100,001 and $250,000 in STERIS stock on August 25th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Wabtec (NYSE:WAB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Viking (NYSE:VIK) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Trimble (NASDAQ:TRMB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Transdigm Group (NYSE:TDG) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Tractor Supply (NASDAQ:TSCO) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Middleby (NASDAQ:MIDD) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Somnigroup International (NYSE:SGI) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Signet Jewelers (NYSE:SIG) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Paychex (NASDAQ:PAYX) on 8/25/2026.

STERIS Stock Down 0.6%

Shares of STE stock traded down $1.35 during trading hours on Friday, reaching $211.10. 595,400 shares of the company’s stock were exchanged, compared to its average volume of 775,522. The stock’s 50 day moving average is $225.55 and its 200-day moving average is $221.14. The company has a market cap of $20.58 billion, a price-to-earnings ratio of 25.81 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.35 and a debt-to-equity ratio of 0.23. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. The company had revenue of $1.49 billion during the quarter, compared to analysts’ expectations of $1.49 billion. STERIS had a return on equity of 14.34% and a net margin of 13.34%.The firm’s revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business posted $2.34 earnings per share. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Analysts predict that STERIS plc will post 11.09 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Friday, September 4th will be issued a $0.69 dividend. This is an increase from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Friday, September 4th. STERIS’s dividend payout ratio is presently 33.74%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on STE shares. Wall Street Zen upgraded shares of STERIS from a “hold” rating to a “buy” rating in a report on Sunday, August 9th. UBS Group dropped their price objective on shares of STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of STERIS in a research note on Monday, August 24th. Finally, Piper Sandler reissued an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and a consensus price target of $271.33.

Institutional Trading of STERIS

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp boosted its holdings in STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 349 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of STERIS by 32.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after buying an additional 59,264 shares during the last quarter. Empowered Funds LLC raised its position in shares of STERIS by 16.1% during the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 319 shares during the period. Woodline Partners LP raised its position in shares of STERIS by 40.0% during the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after buying an additional 2,372 shares during the period. Finally, Jane Street Group LLC lifted its holdings in STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after acquiring an additional 5,803 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at STERIS

In other STERIS news, Director Mohsen Sohi sold 4,058 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total transaction of $956,795.24. Following the transaction, the director directly owned 24,305 shares in the company, valued at $5,730,632.90. This represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP John Zangerle sold 1,419 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total value of $296,968.32. Following the transaction, the vice president owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.12% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About STERIS

STERIS plc (NYSE: STE) is a global provider of products and services designed to support infection prevention, sterilization, surgical procedures and other critical healthcare and life sciences activities. The company serves hospitals, ambulatory surgery centers, dental practices, pharmaceutical and biotechnology manufacturers, medical device companies, and research organizations.

Its offerings include sterilizers, washers, surgical tables and lights, operating-room equipment, endoscopy products, infection-prevention consumables, and related maintenance and technical services.